Medindia

X

Reportlinker Adds Cell and Stem Cell Therapies for Diabetes

Wednesday, March 3, 2010 General News J E 4
Advertisement


NEW YORK, March 2 Reportlinker.com announces that a new market research report is available in its catalogue:

Cell and Stem Cell Therapies for Diabetes

http://www.reportlinker.com/p0180000/Cell-and-Stem-Cell-Therapies-for-Diabetes.html

Summary

In 2030, three leading countries with diabetes population, India, China and the USA, will have over 150 million people with diabetes. For the USA, researchers from the University of Chicago (USA) forecast that in the next 25 years, the size of the USA population with diabetes, both diagnosed and undiagnosed, will rise from approximately 24 million now to 44 million by the year 2034. Economic impact of diabetes is enormous.

During the period of next 25 years, the USA annual diabetes-related spending is expected to increase from $113 billion to $336 billion, and in the period from 2006-2015, China will lose at least $558 billion of its national income due to the combination of heart disease, stroke and diabetes. Pancreatic islet cell transplantation and particularly stem cell-based therapies have a huge potential to restore glucose control in patients with diabetes, without risk of serious hypoglycemic adverse effects associated with insulin therapy, and safety issues of other anti-diabetes treatments. Recent investigations in the area of regeneration of insulin-producing cells reveals that, in addition to primary source, pancreatic islet cells, insulin-producing cells can be derived from several other sources, including adult mesenchymal and hematopoetic stem cells, induced pluripotent stem cells, engineered stem cells, and embryonic stem cells.

BioPolaris' Cell and Stem Cell Therapies for Diabetes report addresses the recent advances in research and development of pancreatic islet cell and stem cell therapies for the treatment of diabetes. BioPolaris research reveals that Cell and Stem Cell Therapies for Diabetes R & D pipeline contains 19 products in development. Four of them are islet cells (21%), ten are various adult stem cells and their progeny (53%), and five (26%) are embryonic-like stem cells-derived insulin-producing cells. Out of ten products using adult stem cells only three (30%) are autotransplants, significantly less than in other adult stem cells-based pipelines. On the other hand, participation of embryonic and embryonic-like stem cell-based products in this pipeline is the highest in comparison with stem cell-based products for the treatment of cardiac and peripheral arterial diseases, spinal cord injury and stroke.

Despite large research work done in the area of islet cell applications for the treatment of diabetes, and large number of completed and active clinical trials that are evaluating islet cells, currently only four products with islet cells are undergoing development with goal to be commercialized, showing small interest for this type of products among biotechnology companies. And development of two of those products is non-active. Also, porcine islet cells are used for xenotransplantation in only two products. Surprisingly, this is a very young pipeline with 14 out of 19 products (74%) in preclinical stage of development, and only one product in clinical Phase II.

Content

1. Introduction

2. Prevalence of Diabetes Worldwide and in the USA

3. Diabetic Complications

4. Economic Impact of Diabetes

5. Pancreas, Islet Cells and Insulin

6. Cell and Stem Cell Therapies for the Treatment of Diabetes

6.1. Islet Cell Transplantation for the Treatment of Diabetes

6.1.1. Allotransplantation of Islet Cells

6.1.1.1. Regulation of Allotransplantation of Islet Cells

6.1.1.2. Guidance for Allotransplantation of Islet Cells

6.1.2. Xenotransplantation of Islet Cells

6.1.2.1. IXA Recommendations for Xenotransplantation of Pig Islet Cells

6.1.2.2. Genetically engineered pigs

6.1.3. Isolation of Islet Cells from Pancreas

6.1.4. Purification of Islet Cells

6.1.5. Culturing of Islet Cells

6.1.6. Quality of Islet Cells and Transportation Issues

6.1.7. Encapsulation of Islet Cells

6.1.8. Engineered Mature Insulin-Producing Cells

6.1.8.1. Use of Viral Gene Vectors

6.1.8.2. New Polymeric Gene Vectors

6.1.9. Trans-Differentiation of Mature Non-Islet to Islet Cells

6.1.10. Delivery of Islet Cells

6.1.11. Survival of Transplanted Islet Cells

6.1.12. Complications of Islet Cell Transplantation

6.1.13. Results of Clinical Islet Cell Transplantations for the Treatment of Diabetes

6.2. Stem Cells

6.2.1. Adult Stem Cells

6.2.1.1. Origin of Adult Stem Cells

6.2.1.2. Sources of Adult Stem Cells

6.2.1.3. Generation of Progenitor and Mature Cells from Adult Stem Cells

6.2.1.4. Types of Adult Stem Cells

6.2.1.4.1. Mesenchymal Stem Cells (MSCs)

6.2.1.4.2. Pancreatic Mesenchymal Stem Cells

6.2.1.4.3. Mesenchymal-Like Stem Cells

6.2.1.4.4. Pancreatic Stem/Progenitor Cells

6.2.1.5. Advantages and Disadvantages of Adult Stem Cells

6.2.1.6. Types of Adult Stem Cell Transplantations

6.2.1.7. Manipulation of Adult Stem Cells Ex Vivo

6.2.1.7.1. Isolation of Adult Stem Cells

6.2.1.7.2. Expansion of Adult Stem Cells ex Vivo (Bioreactors)

6.2.1.7.3. Adult Stem Cell Differentiation in Vitro (Biochips)

6.2.1.7.4. Encapsulation of Adult Stem Cells

6.2.1.7.5. Cryopreservation of Adult Stem Cells

6.2.1.8. Manipulation of Adult Stem Cells in Vivo

6.2.1.8.1. Activation of Dormant Adult Stem Cells in Vivo

6.2.1.8.2. Stimulation of Proliferation and Differentiation of Adult Stem Cells in Vivo

6.2.1.8.3. Mobilization of Adult Stem Cells in Vivo

6.2.1.9. Effect of Diabetes on Adult Stem/Progenitor Cells

6.2.1.9.1. Effect of Diabetes on Mesenchymal Stem Cells

6.2.1.9.2. Effect of Diabetes on Mononuclear Cells

6.2.1.9.2. Effect of Diabetes on Mononuclear Cells

6.2.1.9.3. Effect of Diabetes on Endothelial Progenitor Cells

6.2.1.9.4. Effect of Diabetes on CD34+ Progenitor Cells

6.2.1.10. Transplantation of Adult Stem Cells for the Treatment of Diabetes

6.2.1.11. Sources of Adult Stem Cells Used for the Treatment of Diabetes

6.2.1.12. Use of Various Adult Stem Cells for the Treatment of Diabetes

6.2.1.12.1. Use of Pancreatic Stem/Progenitor Cells for the Treatment of Diabetes

6.2.1.12.2. Use of Mesenchymal Stem Cells for the Treatment of Diabetes

6.2.1.12.2.1. Subpopulation of Bone Marrow Cells: Very Small Embryonic-Like (VSEL) Cells

6.2.1.12.3. Use of Mesenchymal-Like Stem Cells for the Treatment of Diabetes

6.2.1.12.4. Use of Skin Stem Cells-Derived Insulin-Producing Cells for the Treatment of Diabetes

6.2.1.13. Co-Transplantation of Islet and Adult Stem Cells for the Treatment of Diabetes

6.2.2. Engineered Adult Stem Cells

6.2.3. Embryonic Stem Cells

6.2.3.1. Advantages and Disadvantages of Embryonic Stem Cells for Therapeutic Use

6.2.3.2. Growth of Embryonic Stem Cells

6.2.3.3. Differentiation of Embryonic Stem Cells

6.2.3.4. Differentiation of Embryonic Stem Cells Into Insulin-Producing Cells

6.2.3.4.1. The New Three-Dimensional (3D) Embryonic Stem Cell Pancreatic Differentiation System

6.2.3.5. Delivery of Stem Cells-Differentiated Insulin-Producing Cells for the Treatment of Diabetes

6.2.3.6. Results of Clinical Trials that Evaluated Effects of Stem Cell Transplantation for the Treatment of Diabetes

7. R & D Products Analysis

8. Product Profiles

9. Companies and Investors

10. Company Profiles

11. Conclusion:

A. Tables

Table 1. Fifteen Countries that Will Have the Highest Number of Patients with

Diabetes in 2030

Table 2. Adult Stem Cells-Derived Mature Islet Cells

Table 3. Cell and Stem Cell R & D Therapeutic Products for the Treatment of Diabetes

Table 4. Companies and Investors

B. Illustrations

Illustration 1. Proprietary micmac® cell encapsulation technology.

Illustration 2. DPN® renders precise nanopatterns capable of producing a homogeneous population of

differentiated adult cells.

C. Photos

Photo 1. This is a pancreatic islet from an adult mouse that was immunostained for Sox17 (blue), insulin (red),

and glucagon (green).

To order this report:

Biotechnology Industry: Cell and Stem Cell Therapies for Diabetes

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact: Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Larry Howard Bernstein M.D. is Recognized by Conti...
S
Dr. Richard Merkin, President and CEO, Heritage Pr...